Literature DB >> 189724

Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.

A Rifkin, F Quitkin, C J Rabiner, D F Klein.   

Abstract

In a simple remitted, nonpsychotic schizophrenics, the relapse rate within one year was significantly higher for those patients taking placebo as opposed to those taking fluphenazine hydrochloride orally or fluphenazine decanoate. There were no differences in relapse rates between the two active drugs, but there were significantly more terminations due to toxicity from fluphenazine decanoate than from pluphenazine given orally, entirely due to the fact that in 35% of patients receiving fluphenazine decanoate, severe akinesia developed.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 189724     DOI: 10.1001/archpsyc.1977.01770130045004

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  16 in total

Review 1.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

Review 2.  Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications.

Authors:  S R Marder; J W Hubbard; T Van Putten; K K Midha
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 3.  Drug treatment of schizophrenia in the 1990s. Achievements and future possibilities in optimising outcomes.

Authors:  W W Fleischhacker; M Hummer
Journal:  Drugs       Date:  1997-06       Impact factor: 9.546

4.  What's new in the psychopharmacology of schizophrenia.

Authors:  A Rifkin; F Quitkin
Journal:  Bull N Y Acad Med       Date:  1978-10

5.  Will the new antipsychotics improve the treatment of schizophrenia?

Authors:  T Hale
Journal:  BMJ       Date:  1993-09-25

6.  The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use.

Authors:  Maju Mathew Koola; Heidi J Wehring; Deanna L Kelly
Journal:  J Dual Diagn       Date:  2012

7.  Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.

Authors:  Taishiro Kishimoto; Alfred Robenzadeh; Claudia Leucht; Stefan Leucht; Koichiro Watanabe; Masaru Mimura; Michael Borenstein; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2012-12-17       Impact factor: 9.306

8.  Outcome and risks of ultra-long-term treatment with an oral neuroleptic drug. Relationship between perazine serum levels and clinical variables in schizophrenic outpatients.

Authors:  A Pietzcker; A Poppenberg; J Schley; B Müller-Oerlinghausen
Journal:  Arch Psychiatr Nervenkr (1970)       Date:  1981

Review 9.  Fluphenazine (oral) versus placebo for schizophrenia.

Authors:  Hosam E Matar; Muhammad Qutayba Almerie; Stephanie Sampson
Journal:  Cochrane Database Syst Rev       Date:  2013-07-17

Review 10.  Long-term depot antipsychotics. A risk-benefit assessment.

Authors:  T R Barnes; D A Curson
Journal:  Drug Saf       Date:  1994-06       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.